A5000787182- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Synthesis and biological activity
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Musculoskeletal synovial abnormalities and treatments
- Immune cells in cancer
- Virus-based gene therapy research
- Tendon Structure and Treatment
- Viral gastroenteritis research and epidemiology
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Dietetics, Nutrition, and Education
- Helicobacter pylori-related gastroenterology studies
- Protease and Inhibitor Mechanisms
- Chronic Lymphocytic Leukemia Research
- Cancer, Stress, Anesthesia, and Immune Response
- Neurotransmitter Receptor Influence on Behavior
- Forensic Toxicology and Drug Analysis
- HIV Research and Treatment
- Sarcoma Diagnosis and Treatment
Pfizer (United Kingdom)
2019-2024
Background This phase 1b study ( NCT02323191 ) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab patients advanced solid tumors naïve or experienced for immune checkpoint blockers (ICBs). Methods Emactuzumab (500–1350 mg flat) (1200 were administered intravenously every 3 weeks. Dose...
Background This phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluster differentiation 40 mAb) patients advanced solid tumors. Methods Both were administered intravenously every 3 weeks doses concomitantly escalated (emactuzumab: 500 to 1000 mg flat; selicrelumab: 2 16 flat). Dose escalation was conducted using...
Purpose: Simlukafusp alfa [fibroblast activation protein α–targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast α. This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity of FAP-IL2v in patients advanced/metastatic solid tumors. Patients Methods: Participants received...
This study investigated the safety, clinical activity and patient-reported outcomes of patients with diffuse-type tenosynovial giant-cell tumour (dTGCT) soft tissue who were treated emactuzumab, a humanised anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody followed up for to 2 years after start treatment.In this open-label phase (ClinicalTrials.govNCT01494688), received intravenous (IV) emactuzumab from 900 2000 mg every two weeks in dose-escalation at optimal biological...
Macrophage depletion by colony-stimulating factor 1 receptor blockade alters extracellular matrix homeostasis and promotes skin edema.
Abstract Purpose: The immunocytokine cergutuzumab amunaleukin (CEA-IL2v) showed manageable safety and favorable pharmacodynamics in phase I/Ib trials patients with advanced/metastatic carcinoembryonic antigen-positive (CEA+) solid tumors, but this was accompanied by a high incidence of anti-drug antibodies (ADA). We examined B-cell depletion obinutuzumab as potential mitigation strategy. Experimental Design: Preclinical data comparing rituximab versus are summarized. Substudies investigated...
<h3>Background</h3> Selicrelumab is a human IgG2 agonistic anti-CD40 monoclonal antibody. Binding of the antibody to CD40 expressed on antigen-presenting cells results in T- cell priming and T-cell dependent anti-tumor activity. In response activation, tumor express programmed-death ligand 1 (PD-L1) that can suppress effector T-cells. Atezolizumab interrupts this feedback loop by blocking PD-L1, thereby supporting combination with selicrelumab. <h3>Methods</h3> This phase Ib open-label,...
<p>Supplementary Figure S1. design. FAP-IL2v, fibroblast activation protein-α interleukin-2 variant; PD, progressive disease; QW, weekly.</p>
<div>Purpose:<p>Simlukafusp alfa [fibroblast activation protein α–targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast α. This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity of FAP-IL2v in patients advanced/metastatic solid tumors.</p>Patients...
<p>Supplementary Figure S1. design. FAP-IL2v, fibroblast activation protein-α interleukin-2 variant; PD, progressive disease; QW, weekly.</p>
<p>Supplementary Methods</p>
<p>Supplementary Methods</p>
<div>Purpose:<p>Simlukafusp alfa [fibroblast activation protein α–targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast α. This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity of FAP-IL2v in patients advanced/metastatic solid tumors.</p>Patients...
<p>Supplementary Figure S1. The effect of obinutuzumab pretreatment on A, De-novo vaccination with tetanus toxoid and B, Memory re-call to immune rechallenge a measles/rubella in cynomolgus monkeys.</p>
<p>Supplementary Figure S2. Percent reduction in B cell numbers and cell/T ratios human CD20 transgenic mice treated with obinutuzumab or rituximab A, Spleen B, Lymph nodes. C, Reduction splenic marginal zone cells (n = 2 per group).</p>
<p>Supplementary Figure S3. Efficacy of IL-2v alone and in combination with anti-PD-L1 A, Wild-type C57BL/6 mice B, B-cell deficient mice. IL-2v, interleukin-2 variant; PD-L1, programmed death-ligand 1.</p>